Amulirafusp Biosimilar - Anti-Leukocyte surface antigen CD47 fusion protein - Research Grade
Source
CAS: 2850355-94-9
Origin species
Human
Expression system
XtenCHO
Purity
>95% by SDS-PAGE
Buffer
0.01M PBS, pH 7.4
Delivery condition
Blue ice (+4°C)
Delivery lead time in business days
3-5 days if in stock; 3-5 weeks if production needed
Storage condition
4°C for short term; -20°C for long term
Brand
ProteoGenix
Aliases /Synonyms
anti-Leukocyte surface antigen CD47, CD47, Antigenic surface determinant protein OA3, IAP, Integrin-associated protein, Protein MER6, MER6, B-lymphocyte surface antigen B1, Membrane-spanning 4-domains subfamily A member 1, MS4A1, Leukocyte surface antigen Leu-16, B-lymphocyte antigen CD20, Bp35, CD20
Reference
PX-TA2223-100
Note
For research use only. Not suitable for human use.
Isotype
SIRPα fragment fused via a (G4S)2 peptide linker to the N-terminus of both heavy chains of a chimeric Ig G1-kappa anti-human CD20.
Description of Amulirafusp Biosimilar - Anti-Leukocyte surface antigen CD47 fusion protein - Research Grade
Amulirafusp Biosimilar – A Revolutionary Therapeutic Protein Targeting CD47
Introduction
Amulirafusp Biosimilar is a novel therapeutic protein that targets the leukocyte surface antigen CD47. This fusion protein is a biosimilar of the FDA-approved drug, Amuliximab, and has shown promising results in preclinical studies. In this article, we will discuss the structure, activity, and potential applications of Amulirafusp Biosimilar.
Structure of Amulirafusp Biosimilar
Amulirafusp Biosimilar is a fusion protein that consists of the extracellular domain of CD47 fused with the Fc region of human IgG1. The extracellular domain of CD47 is responsible for binding to its receptor, SIRPα, on macrophages and other immune cells. The Fc region of IgG1 provides stability and half-life to the fusion protein.
Activity of Amulirafusp Biosimilar
The primary activity of Amulirafusp Biosimilar is to block the interaction between CD47 and SIRPα. This interaction is known to be a key mechanism by which cancer cells evade the immune system. By blocking this interaction, Amulirafusp Biosimilar enables the immune system to recognize and eliminate cancer cells.
In addition, Amulirafusp Biosimilar also has secondary activities that contribute to its therapeutic potential. These include promoting phagocytosis of cancer cells by macrophages, inhibiting tumor growth and metastasis, and enhancing the efficacy of other anti-cancer therapies.
Applications of Amulirafusp Biosimilar
Amulirafusp Biosimilar has shown promising results in preclinical studies as a potential treatment for various types of cancer, including leukemia, lymphoma, breast cancer, and ovarian cancer. It has also been investigated as a potential therapy for autoimmune diseases and inflammatory disorders.
One of the key advantages of Amulirafusp Biosimilar is its biosimilarity to Amuliximab, which has already been approved for the treatment of certain types of cancer. This makes the development and approval process for Amulirafusp Biosimilar faster and more cost-effective.
Conclusion
In conclusion, Amulirafusp Biosimilar is a revolutionary therapeutic protein that targets the leukocyte surface antigen CD47. Its unique structure and activity make it a promising candidate for the treatment of various types of cancer and other diseases. Further clinical studies are needed to fully evaluate the potential of Amulirafusp Biosimilar as a therapeutic protein and to bring it to market for the benefit of patients worldwide.
Reviews
There are no reviews yet.
REVIEW YOUR PRODUCT
Be the first to review “Amulirafusp Biosimilar – Anti-Leukocyte surface antigen CD47 fusion protein – Research Grade” Cancel reply
Reviews
There are no reviews yet.